137 related articles for article (PubMed ID: 11400119)
1. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer.
Egawa C; Miyoshi Y; Takamura Y; Taguchi T; Tamaki Y; Noguchi S
Int J Cancer; 2001 Jul; 95(4):255-9. PubMed ID: 11400119
[TBL] [Abstract][Full Text] [Related]
2. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
Miyoshi Y; Ando A; Takamura Y; Taguchi T; Tamaki Y; Noguchi S
Int J Cancer; 2002 Jan; 97(1):129-32. PubMed ID: 11774254
[TBL] [Abstract][Full Text] [Related]
3. Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers.
Takamura Y; Kobayashi H; Taguchi T; Motomura K; Inaji H; Noguchi S
Int J Cancer; 2002 Mar; 98(3):450-5. PubMed ID: 11920599
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers.
Egawa C; Motomura K; Miyoshi Y; Takamura Y; Taguchi T; Tamaki Y; Inaji H; Koyama H; Noguchi S
Breast Cancer Res Treat; 2003 Mar; 78(1):45-50. PubMed ID: 12611456
[TBL] [Abstract][Full Text] [Related]
5. Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers.
Miyoshi Y; Taguchi T; Kim SJ; Tamaki Y; Noguchi S
Breast Cancer; 2005; 12(1):11-5. PubMed ID: 15657517
[TBL] [Abstract][Full Text] [Related]
6. Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.
Takahashi Y; Miyoshi Y; Morimoto K; Taguchi T; Tamaki Y; Noguchi S
J Cancer Res Clin Oncol; 2007 Aug; 133(8):501-9. PubMed ID: 17297610
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
[TBL] [Abstract][Full Text] [Related]
8. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers.
Hasegawa S; Miyoshi Y; Egawa C; Ishitobi M; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2003 Aug; 9(8):2992-7. PubMed ID: 12912947
[TBL] [Abstract][Full Text] [Related]
9. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Andres JL; Fan S; Turkel GJ; Wang JA; Twu NF; Yuan RQ; Lamszus K; Goldberg ID; Rosen EM
Oncogene; 1998 Apr; 16(17):2229-41. PubMed ID: 9619832
[TBL] [Abstract][Full Text] [Related]
10. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer.
Kim SJ; Miyoshi Y; Taguchi T; Tamaki Y; Nakamura H; Yodoi J; Kato K; Noguchi S
Clin Cancer Res; 2005 Dec; 11(23):8425-30. PubMed ID: 16322305
[TBL] [Abstract][Full Text] [Related]
11. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
Ooe A; Kato K; Noguchi S
Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of docetaxel for recurrent breast cancer: evaluation based on chemosensitivity test and clinical response].
Sakurai T; Tanino H; Oura S; Suzuma T; Yamamiti N; Yoshimasu T; Sakurai T; Naito Y
Gan To Kagaku Ryoho; 2000 Mar; 27(3):423-7. PubMed ID: 10740636
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.
Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Cancer Sci; 2018 Jan; 109(1):166-173. PubMed ID: 29047188
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics.
Egawa C; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
Jpn J Cancer Res; 2001 Jun; 92(6):624-30. PubMed ID: 11429050
[TBL] [Abstract][Full Text] [Related]
16. Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.
Witters LM; Santala SM; Engle L; Chinchilli V; Lipton A
Am J Clin Oncol; 2003 Feb; 26(1):50-4. PubMed ID: 12576925
[TBL] [Abstract][Full Text] [Related]
17. [A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
Oura S; Tanino H; Yoshimasu T; Sakurai T; Nakamura T; Kokawa Y; Matsuyama K; Naito Y
Gan To Kagaku Ryoho; 2001 Apr; 28(4):511-4. PubMed ID: 11329786
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
Smith IC; Heys SD; Hutcheon AW; Miller ID; Payne S; Gilbert FJ; Ah-See AK; Eremin O; Walker LG; Sarkar TK; Eggleton SP; Ogston KN
J Clin Oncol; 2002 Mar; 20(6):1456-66. PubMed ID: 11896092
[TBL] [Abstract][Full Text] [Related]
19. 70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers.
Naoi Y; Tanei T; Kishi K; Tsunashima R; Tominaga N; Baba Y; Nakayama T; Shimazu K; Kim SJ; Tamaki Y; Noguchi S
Cancer Lett; 2012 Jan; 314(2):206-12. PubMed ID: 22018777
[TBL] [Abstract][Full Text] [Related]
20. The international experience with docetaxel in the treatment of breast cancer.
Ravdin PM
Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):38-42. PubMed ID: 9110341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
